Zydus Lifesciences Ltd (BOM:532321)
₹ 1058.55 -17.35 (-1.61%) Market Cap: 1.07 Til Enterprise Value: 1.05 Til PE Ratio: 28.21 PB Ratio: 5.46 GF Score: 95/100

Q2 2022 Cadila Healthcare Ltd Earnings Call Transcript

Oct 29, 2021 / 10:30AM GMT
Release Date Price: ₹503.2 (+2.32%)
Operator

Ladies and gentleman, good day and welcome to the Cadila Healthcare Limited, Q2 FY '22 Post Results Conference Call. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Ganesh Nayak, Executive Director, Cadila Healthcare. Thank you, and over to you, sir.

Ganesh Narayan Nayak
Cadila Healthcare Limited - COO & Executive Director

Good evening, ladies and gentlemen. Welcome to our post results teleconference for the quarter ended September 30, '21. I do wish that you and your family members are keeping safe and well. For today's call, we have with us Dr. Sharvil Patel, Managing Director; Mr. Nitin Parekh, Chief Financial Officer; and Mr. Vishal Gor, Senior Vice President, Corporate Finance. I'm sure you would have gone through the quarterly results investor presentation, which we have posted on our website and filled with the stock exchanges.

The quarter gone by was a promising one for our India geography, as it continued to build on the momentum and recorded a double-digit growth

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot